Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1$\alpha$ Stability in Aerobic Conditions
Authors
Costa, Ana SH
Grice, Guinevere L
Lobb, Ian
Freisinger, Peter
Publication Date
2016-10-27Journal Title
Cell Metabolism
ISSN
1550-4131
Publisher
Elsevier (Cell Press)
Volume
24
Pages
740-752
Language
English
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Burr, S., Costa, A. S., Grice, G. L., Timms, R., Lobb, I., Freisinger, P., Dodd, R., et al. (2016). Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1$\alpha$ Stability in Aerobic Conditions. Cell Metabolism, 24 740-752. https://doi.org/10.1016/j.cmet.2016.09.015
Abstract
Hypoxia-inducible transcription factors (HIFs) control adaptation to low oxygen environments by activating genes involved in metabolism, angiogenesis, and redox homeostasis. The finding that HIFs are also regulated by small molecule metabolites highlights the need to understand the complexity of their cellular regulation. Here we use a forward genetic screen in near-haploid human cells to identify genes that stabilize HIFs under aerobic conditions. We identify two mitochondrial genes, oxoglutarate dehydrogenase (OGDH) and lipoic acid synthase (LIAS), which when mutated stabilize HIF1$\alpha$ in a non-hydroxylated form. Disruption of OGDH complex activity in OGDH or LIAS mutants promotes L-2-hydroxyglutarate formation, which inhibits the activity of the HIF$\alpha$ prolyl hydroxylases (PHDs) and TET 2-oxoglutarate dependent dioxygenases. We also find that PHD activity is decreased in patients with homozygous germline mutations in lipoic acid synthesis, leading to HIF1 activation. Thus, mutations affecting OGDHC activity may have broad implications for epigenetic regulation and tumorigenesis.
Sponsorship
This work was supported by a Wellcome Trust Senior Clinical Research Fellowship to J.A.N. (102770/Z/13/Z), Wellcome Trust Principal Research Fellowship to P.J.L. (084957/Z/08/Z), and the Medical Research Council (A.S.H.C. and C.F.). The Cambridge Institute for Medical Research is in receipt of a Wellcome Trust Strategic Award (100140).
Funder references
Wellcome Trust (102770/Z/13/Z)
Medical Research Council (MC_UU_12022/6)
Wellcome Trust (101835/Z/13/Z)
MRC (MC_UU_12022/1_do not transfer?)
Wellcome Trust (100140/Z/12/Z)
Wellcome Trust (084957/Z/08/Z)
Embargo Lift Date
2100-01-01
Identifiers
External DOI: https://doi.org/10.1016/j.cmet.2016.09.015
This record's URL: https://www.repository.cam.ac.uk/handle/1810/261231
Rights
Attribution 4.0 International, Attribution 4.0 International, Attribution 4.0 International
Recommended or similar items
The following licence files are associated with this item: